What is HC Wainwright’s Forecast for RNAC FY2027 Earnings?

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) – Research analysts at HC Wainwright issued their FY2027 earnings per share estimates for shares of Cartesian Therapeutics in a research report issued on Tuesday, May 12th. HC Wainwright analyst M. Kapoor expects that the company will earn ($3.79) per share for the year. HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Cartesian Therapeutics’ current full-year earnings is ($3.93) per share.

Cartesian Therapeutics (NASDAQ:RNAC) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($1.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.62). The firm had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.22 million.

Other research analysts also recently issued research reports about the company. BTIG Research reissued a “buy” rating on shares of Cartesian Therapeutics in a research note on Monday, March 9th. Cantor Fitzgerald upgraded shares of Cartesian Therapeutics from a “neutral” rating to an “overweight” rating and set a $16.00 price objective for the company in a research report on Monday, March 9th. Needham & Company LLC restated a “buy” rating and issued a $42.00 price objective on shares of Cartesian Therapeutics in a research report on Monday, March 9th. Wedbush restated an “outperform” rating and issued a $38.00 price objective on shares of Cartesian Therapeutics in a research report on Friday, May 1st. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Cartesian Therapeutics in a research report on Friday, March 27th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Cartesian Therapeutics has an average rating of “Moderate Buy” and an average target price of $33.00.

Cartesian Therapeutics Stock Up 2.0%

RNAC stock opened at $8.70 on Wednesday. The business’s fifty day moving average is $6.95 and its 200-day moving average is $7.22. The company has a market cap of $255.61 million, a P/E ratio of -1.47 and a beta of 0.58. Cartesian Therapeutics has a twelve month low of $5.60 and a twelve month high of $15.57.

Hedge Funds Weigh In On Cartesian Therapeutics

Hedge funds have recently modified their holdings of the stock. Privium Fund Management B.V. acquired a new stake in Cartesian Therapeutics in the 4th quarter valued at about $1,244,000. R Squared Ltd acquired a new stake in Cartesian Therapeutics in the 4th quarter valued at about $74,000. AlphaQuest LLC lifted its stake in Cartesian Therapeutics by 64.6% in the 3rd quarter. AlphaQuest LLC now owns 6,924 shares of the company’s stock valued at $71,000 after purchasing an additional 2,717 shares during the last quarter. Marshall Wace LLP lifted its stake in Cartesian Therapeutics by 114.0% in the 2nd quarter. Marshall Wace LLP now owns 82,630 shares of the company’s stock valued at $859,000 after purchasing an additional 44,025 shares during the last quarter. Finally, Walleye Capital LLC acquired a new stake in Cartesian Therapeutics in the 4th quarter valued at about $316,000. Institutional investors own 86.95% of the company’s stock.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, trading on NASDAQ under the symbol RNAC, is a clinical?stage biotechnology company specializing in the development of messenger RNA (mRNA)-based therapeutics. The company leverages a proprietary RNA delivery platform to induce the production of therapeutic proteins within patients, aiming to address a range of diseases through in vivo expression of disease-modifying agents. Cartesian’s technology is designed to optimize mRNA stability, translation efficiency and targeted delivery, with potential applications spanning oncology, autoimmune disorders and rare genetic conditions.

At the core of Cartesian’s approach is a synthetic mRNA platform that incorporates proprietary lipid nanoparticle (LNP) formulations.